XML 78 R19.htm IDEA: XBRL DOCUMENT
v3.20.4

Restructuring and Other Charges (Income) | 12 Months Ended
--- | ---
Dec. 31, 2020
Restructuring and Related Activities [Abstract] |
Restructuring and Other Charges (Income) | Restructuring and Other Charges (Income) The following table shows total restructuring and other charges (income) included in the respective line items of the consolidated statements of income (loss):
| Year Ended December 31,
(in Millions) | 2020 |  | 2019 |  | 2018
Restructuring charges | $ | 42.6 |  |  | $ | 62.2 |  |  | $ | 124.1 |
Other charges (income), net | 89.6 |  |  | 108.8 |  |  | (62.9) |
Total restructuring and other charges (income) | $ | 132.2 |  |  | $ | 171.0 |  |  | $ | 61.2 |
Restructuring charges
(in Millions) | Severance and Employee Benefits |  | Other Charges (Income) (1) |  | Asset Disposal Charges (2) |  | Total
DuPont Crop restructuring | $ | 9.2 |  |  | $ | 3.8 |  |  | $ | 27.2 |  |  | $ | 40.2 |
Other items | 2.8 |  |  | — |  |  | (0.4) |  |  | 2.4 |
Year ended December 31, 2020 | $ | 12.0 |  |  | $ | 3.8 |  |  | $ | 26.8 |  |  | $ | 42.6 |
DuPont Crop restructuring | $ | 9.1 |  |  | $ | 5.2 |  |  | $ | 12.1 |  |  | $ | 26.4 |
Furadan® product exit | — |  |  | — |  |  | 34.1 |  |  | 34.1 |
Other items | 1.7 |  |  | — |  |  | — |  |  | 1.7 |
Year ended December 31, 2019 | $ | 10.8 |  |  | $ | 5.2 |  |  | $ | 46.2 |  |  | $ | 62.2 |
DuPont Crop restructuring | $ | 16.3 |  |  | $ | 16.9 |  |  | $ | 75.1 |  |  | 108.3 |
Other items | 5.7 |  |  | 3.1 |  |  | 7.0 |  |  | 15.8 |
Year ended December 31, 2018 | $ | 22.0 |  |  | $ | 20.0 |  |  | $ | 82.1 |  |  | $ | 124.1 |
____________________ (1)Primarily represents third-party costs associated with miscellaneous restructuring activities. Other income, if applicable, primarily represents favorable developments on previously recorded exit costs and recoveries associated with restructuring. (2)Primarily represents asset write-offs (recoveries), and accelerated depreciation and impairment charges on long-lived assets, which were or are to be abandoned. To the extent incurred, the acceleration effect of re-estimating settlement dates and revised cost estimates associated with asset retirement obligations due to facility shutdowns, are also included within the asset disposal charges. Furadan® Product Exit During the fourth quarter of 2019, we decided to exit sales of all carbofuran formulations (including Furadan® insecticide/nematicide, Curaterr® insecticide/nematicide and any other brands used with carbofuran products) globally effective December 31, 2019. As a result of this decision, we accelerated the recognition of asset retirement obligations and asset write offs associated with the exit. DuPont Crop Restructuring On November 1, 2017, we completed the acquisition of the DuPont Crop Protection Business. See Note 5 "Acquisitions" for more details. As also discussed in Note 5, we completed the integration of the DuPont Crop Protection Business except for the completion of certain in-flight initiatives including the DuPont Crop restructuring program as of June 30, 2020. Estimated remaining restructuring charges are expected to be less than $5 million primarily associated with accelerated depreciation on certain fixed assets, severance, and other costs as we exit certain facilities. For the years ended December 31, 2020 and 2019, we incurred restructuring charges of $40.2 million and $26.4 million, respectively, which primarily represented severance and other employee related costs as well as accelerated depreciation on fixed assets for the planned exit of certain facilities. 2018 Activities For the year ended December 31, 2018, we incurred restructuring charges of $108 million. $63 million of these charges were related to a significant change to how we operate in the market in the combined business in India. On July 3, 2018, we announced the adoption of an innovation-focused product strategy that uses a unique market access model anchored by our key, large scale distributors rather than the vast customer base we served prior to the DuPont Crop Protection Acquisition. Additionally, we rationalized our product portfolio and decisively exited a vast majority of the low margin product range. As a result of the change to our market access, we incurred charges of approximately $59 million, which primarily included the write-off of stranded accounts receivables and inventory. We also had workforce reductions which resulted in severance and other employee benefit charges of approximately $4 million. $27.8 million of the 2018 restructuring charges related to our decision to migrate our Ewing R&D activities and employees into the newly acquired Stine R&D facilities due to their close proximity to one another. We incurred charges of $17.4 million of accelerated depreciation charges of certain fixed assets that will no longer be used due to our exit from the facility. The cease use criteria was met as of September 30, 2018 as all employees had exited the Ewing facility and the facility became available for use. We recorded the estimated future liability associated with the rental obligation on the cease use date which resulted in a charge of $11.2 million. This charge was offset by the reduction of the capital lease liability previously recorded in "Other long- term liabilities" of $6.0 million. In addition to lease termination costs, we incurred severance, relocation and other employee related charges of $5.2 million for combined charges of $27.8 million for the year for this restructuring initiative. Roll forward of restructuring reserves The following table shows a roll forward of restructuring reserves that will result in cash spending. These amounts exclude asset retirement obligations:
(in Millions) | Balance at 12/31/18 |  | Change in reserves (3) |  | Cash payments |  | Other (4) |  | Balance at 12/31/19 (5) |  | Change in reserves (3) |  | Cash payments (5) |  | Other (4) |  | Balance at 12/31/20 (6)
DuPont Crop restructuring (1) | $ | 16.2 |  |  | $ | 14.3 |  |  | $ | (15.9) |  |  | $ | (0.1) |  |  | $ | 14.5 |  |  | $ | 13.0 |  |  | $ | (14.2) |  |  | $ | 0.3 |  |  | $ | 13.6 |
Other workforce related and facility shutdowns (2) | 1.0 |  |  | 1.7 |  |  | (2.7) |  |  | 0.1 |  |  | 0.1 |  |  | 2.8 |  |  | (0.1) |  |  | — |  |  | 2.8 |
Total | $ | 17.2 |  |  | $ | 16.0 |  |  | $ | (18.6) |  |  | $ | — |  |  | $ | 14.6 |  |  | $ | 15.8 |  |  | $ | (14.3) |  |  | $ | 0.3 |  |  | $ | 16.4 |
____________________ (1)Primarily consists of real estate exit costs and severance associated with DuPont Crop restructuring activities. (2)Primarily severance costs related to workforce reductions and facility shutdowns described in the Other items section of the Restructuring charges table above. (3)Primarily severance, exited lease, contract termination and other miscellaneous exit costs. The accelerated depreciation and impairment charges noted above impacted our property, plant and equipment or intangible balances and are not included in this table. (4)Primarily foreign currency translation adjustments. (5)In addition to the spend above there was also $3.6 million of spending related to the Furadan® asset retirement obligation. (6)Included in "Accrued and other liabilities" and "Other long-term liabilities" on the consolidated balance sheets. Other charges (income), net
| Year Ended December 31,
(in Millions) | 2020 |  | 2019 |  | 2018
Environmental charges, net | $ | 24.9 |  |  | $ | 108.7 |  |  | $ | 21.7 |
Product portfolio sales | — |  |  | 0.1 |  |  | (87.2) |
Isagro Fluindapyr Acquisition | 65.6 |  |  | — |  |  | — |
Other items, net | (0.9) |  |  | — |  |  | 2.6 |
Other charges (income), net | $ | 89.6 |  |  | $ | 108.8 |  |  | $ | (62.9) |
Environmental charges, net Environmental charges represent the net charges associated with environmental remediation at continuing operating sites. Environmental obligations for continuing operations primarily represent obligations at shut down or abandoned facilities within businesses that do not meet the criteria for presentation as discontinued operations. During the fourth quarter of 2019, we recorded a charge of $72.8 million as a result of an unfavorable court ruling we received in relation to the Pocatello Tribal Litigation at one of our environmental sites. We remeasure our discounted liability balance according to current interest rates. See Note 12 for further information regarding this matter. Isagro Fluindapyr Acquisition In May 2020, FMC entered into a binding offer with Isagro S.p.A ("Isagro") to acquire the remaining rights for Fluindapyr active ingredient assets from Isagro. In July 2020, we entered into an asset sale and purchase agreement with Isagro. On October 2, 2020, we closed on the transaction with a purchase price of approximately $65 million. Fluindapyr has been jointly developed by FMC and Isagro under a 2012 research and development collaboration agreement. The transaction provides FMC with full global rights to the Fluindapyr active ingredient, including key U.S., European, Asian, and Latin American fungicide markets. The transaction transfers to FMC all intellectual property, know-how, registrations, product formulations and other global assets of the proprietary broad-spectrum fungicide molecule. The Fluindapyr acquisition does not meet the criteria within ASC 805 to qualify as a business and as a result it is treated as an asset acquisition. Based on the current development stage of the technology, the acquired assets have been classified as in-process research and development. As part of our evaluation, we consider the current development phase of the molecule being acquired. Molecules that have not received formal regulatory approval are still considered in process due to the inherent uncertainty with the approval process. As a result, these assets were immediately expensed. While this transaction resulted in an immediate expense of the purchase price under the accounting rules, this acquisition expands our fungicide portfolio by giving us full global rights to the Fluindapyr active ingredient and is an important strategic addition to our product line. We recorded charges totaling $65.6 million for the year, including transaction costs. Product portfolio sales On February 1, 2018, we sold a portion of our European herbicide portfolio to Nufarm Limited. Additionally, on August 16, 2018, we completed the sale of certain products of our India portfolio to Crystal Crop Protection Limited. Both sales were required by regulatory authorities as part of closing conditions for the DuPont Crop Protection Business Acquisition. The gain on these sales are recorded within "Restructuring and other charges (income)" on the consolidated statements of income (loss). Proceeds from these sales are included in investing activities on the consolidated statements of cash flows. Other items, net Other items, net in 2020 were not material. In 2018, other items, net primarily represents a milestone payment on an agreement related to our in-process research and development. Other items, net also includes the loss associated with the divestment of a joint venture.

X
- Definition This describes the aggregate amount provided for estimated restructuring charges, remediation costs, gains on sale of assets, in process research and development acquired as part of an asset acquisition, asset impairment losses and other miscellaneous charges to income during an accounting period. Generally, these items are either unusual or infrequent, but not both (in which case they would be extraordinary items). + References No definition available. + Details
Name: | fmc_RestructuringAndOtherChargesIncomeDisclosureTextBlock
Namespace Prefix: | fmc_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RestructuringAndRelatedActivitiesAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration